Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intravenous immunoglobulin + steroids
- Development stage
- Unknown
- Lead developer
- CSL Behring
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Intravenous immunoglobulin + steroids is a combination regimen pairing intravenous immunoglobulin (IVIG), a pooled human plasma-derived polyclonal IgG biologic, with a corticosteroid (such as methylprednisolone or prednisolone). This combination is widely used as an immunomodulatory and anti-inflammatory therapy in clinical practice. It is recommended as a first-line treatment for multisystem inflammatory syndrome in children (MIS-C) and is also utilized in Kawasaki disease, particularly in IVIG non-responders. Other clinical applications include relapsed adult immune thrombocytopenia (ITP), febrile refractory status epilepticus, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and pediatric acute myocarditis. The regimen leverages the broad immunomodulatory effects of IVIG (such as Fc receptor blockade and cytokine neutralization) alongside the potent anti-inflammatory and immunosuppressive actions of glucocorticoids.
- Other names
- IVIG + corticosteroidsIVIG + steroidsIVIg + methylprednisoloneIVIg + prednisoloneintravenous immunoglobulin + corticosteroidsintravenous immunoglobulin + methylprednisoloneintravenous immunoglobulin + prednisolone
02
Targets
FCGR2B (Fc gamma receptor IIB)GR (Glucocorticoid receptor)FCGRT (Neonatal crystallizable fragment receptor)
Beyond the preview
Go deeper on intravenous immunoglobulin + steroids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intravenous immunoglobulin + steroids.